Skip to main content

Table 1 Trial characteristics

From: European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention—part 1: amitriptyline

Study

Registration

Funding

Country

Mean age

% Male

Duration of migraine (years)

% Aura

Migraine days per month at baseline

Interventions

Number of patients

Couch 1979 [30]

NR

Merck Laboratories

US

NR

16.0

NR

NR

NR

Amitriptyline 100 mg/day or MTD, titrated over 4 weeks, maintained for 4 weeks, oral

Placebo

100

Couch 2011 [32]

NR

Merck, Sharp, and Dohme Research Laboratories

US

34.9

19.0

NR

NR

NR

Amitriptyline 100 mg/day or MTD, titrated over 4 weeks, maintained for 12 weeks, oral

Placebo

391

Gonçalves 2016 [33]

NCT 01357031

Fundação de Amparo a Pesquisa de São Paulo

Brazil

36.9

24.6

22.2

16.1

7.3

Amitriptyline 25 mg/day for 12 weeks

Placebo

131

  1. NR not reported, NCT number clinical trial, MTD maximum tolerable dose